3SBio Inc. (HKG: 1530)

Market Cap	14.15B
Revenue (ttm)	9.05B
Net Income (ttm)	1.78B
Shares Out	2.36B
EPS (ttm)	0.73
PE Ratio	8.21
Forward PE	5.94
Dividend	0.25 (4.16%)
Ex-Dividend Date	Jul 22, 2024

Volume	941,500
Average Volume	7,447,849
Open	6.20
Previous Close	6.21
Day's Range	5.99 - 6.22
52-Week Range	4.91 - 7.85
Beta	0.71
RSI	48.34
Earnings Date	Mar 21, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,411
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1530

Financial Performance

In 2023, 3SBio's revenue was 7.82 billion, an increase of 13.84% compared to the previous year's 6.87 billion. Earnings were 1.55 billion, a decrease of -19.13%.

Financial numbers in CNY